Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates

Postoperative adjuvant immunotherapy for pathological stage II–IVa esophageal squamous cell carcinoma after radical surgery does not improve disease-free recurrence rates

Background/objectivesPostoperative adjuvant therapy for esophageal squamous cell carcinoma (ESCC) primarily includes chemotherapy and chemoradiotherapy. The survival benefits of postoperative adjuvant therapy for R0-resected ESCC remain controversial. Immunotherapy is being gradually applied periope...

Full description

Saved in:
Bibliographic Details
Main Authors: Xihao Xie, Hai Zhang, Haiquan He, Bomeng Wu, Ying Chen, Wanli Lin, Qingyi Feng, Qunqing Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Medicine
Subjects:
adjuvant
chemotherapy
esophageal cancer
immunotherapy
disease-free recurrence rates
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2024.1517001/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1517001/full

Similar Items